New Page
Kristian Andersen: Scripps hotshot - lead-author.
Here's a quote from what i wrote, May 18, 2020 on Fomosahut (the first publication in the world to drill-down on the Prox-O authors, sfaik):
Along with Holmes and Rambaut, Andersen is a genomic surveillance enthusiast:
"We urge those working on infectious disease to focus funds and efforts on a much simpler and more cost-effective way to mitigate outbreaks — proactive, real-time surveillance of human populations."
Andersen works for Scripps Research Institute. Scripps was in financial trouble hemorrhaging 20 mil a year. But just when the first virus cases were emerging, they received great news. They issued a press release Nov 27, 2019:
“Scripps Research and Shenzhen Bay Laboratory (China) today announced a trans-Pacific chemical biology research collaboration that combines the expertise of both institutions.”
Presumably the financial expertise was more from the Chinese side of the equation. Shenzhen City Council and Peking University Shenzhen Graduate School are backing the venture.
"Several Scripps Research chemical biology faculty will establish joint laboratories at Shenzhen Bay Laboratory with research areas including synthetic chemistry, natural products, glycobiology, chemical genetics, proteomics and other critical areas of chemical biology.
"Shenzhen Bay Laboratory (SZBL) is a recently established Guangdong Provincial Laboratory located in the heart of China’s Guangdong-Hong Kong-Macau Greater Bay area. SZBL strives to become a hub for world-class research at the forefront of health science and innovation, spurring novel solutions to the grand issues challenging mankind."
So to break that down: a new bio-tech lab set up in the Hong Kong vicinity with the Hong Kong protest in full swing - in partnership with a financially flailing research institute, whose head scientist is a cheer-leader for genomic surveillance - funded with money from the CCP - in late Nov 2019.
No - nothing fishy about that at all!
Scripps also promotes remdesivir which was also endorsed by WIV. According to this article in Gulf News, Shi Zheng-li’s team “applied for a patent for the drug (remdesivir) in China on behalf of WIV.”
(Note: Washington Post: Daszak .. points out that one of his colleagues, Ralph Baric, .. worked with Gilead Sciences to develop the antiviral drug remdesivir and used virus strains that EcoHealth and its Chinese partners identified in the process, putting the United States ahead of the curve.)
Scripps board of directors includes Dr Ge Li, founder of WuXi PharmaTech.
WuXi AppTec website: Ge Li, Ph.D, Chairman and CEO (:)
Scientist and entrepreneur leading WuXi since its founding in 2000. Ph.D. in Organic Chemistry from Columbia University. Awards and honors include "2018 SAPA Distinguished Achievement Award", "2018 The 40 Most Influential People in Pharmaceutical Industry in Commemoration of the 40th Anniversary of Reform and Opening-up", "2016 CBA Brilliant Achievement Award".
CBA stands for Chinese Biopharmaceutical Association, USA.
-------------
Garry describes Andersen as a generational scientist - the two are long-term collaborators/friends. Andersen is a founding member of the Viral Hemorrhagic Fever Consortium (with Garry), which was accused of causing the 2014 Ebola outbreak in West Africa. He co-authored Ebola Evolution with Holmes and Rambaut - a false narrative writing exercise (pub by Nature) that bears all the hallmarks of being a Prox-O blueprint (swap pangolin for toddler encountering bat in hollow tree (that was burnt to the ground) in remote village)
A big-data futurist - Once was a Twitter warrior - closed his account when the battle heated-up with Drastic.
KG: In the arms race between host and pathogen, there can only be one winner. Unfortunately for the human host, when the opponent is a highly severe virus, the result is often in favor of the pathogen.
(especially with a little help from THE science)
In the arms race for bioweapons research, caused by a fear of non-existent bioterrorists, the result is always in favour of the bio-scientists.